Market Insights

AMCP brought together experts to learn about food allergies caused by the body reacting strongly to certain foods. Food allergies can be difficult to handle and costly for both people and the health care system. New medicines could help prevent allergic reactions, including anaphylaxis, caused by accidental exposure to foods. It is important for health care leaders to make sure people with food allergies see the right doctors, get the right medicine at the right time, and help prevent allergic reactions and related health care costs.

Hemophilia, sickle cell disease (SCD), and beta thalassemia (β thal) are inherited blood disorders likely to see multiple significant novel therapies approved in the near future, including the possibility for partial or complete cures with gene therapies.

Hear from a panel of experts discussing bridging the gaps in precision oncology: opportunities in non-small cell lung cancer

Hear from a panel of experts discussing exploring opportunities to improve quality of life for those with Amyotrophic Lateral Sclerosis (ALS).

Hear from a panel of experts discussing biomarker testing in non-small cell lung cancer

Hear from a panel of experts discussing implementing continuous glucose monitoring interventions to improve outcomes for members with diabetes.

The lack of implementation of predictive biomarkers in clinical practice results in a significant number of individuals with NSCLC not deriving benefits from targeted treatments. Payers have the potential to shape various aspects of the precision oncology pathway, such as addressing biomarker test ordering, utilizing test results to inform treatment decisions, implementing quality measurements, and understanding cost-effectiveness.

Chronic lymphocytic leukemia (CLL) is a chronic lymphoproliferative disorder (lymphoid neoplasm). It is characterized by a progressive accumulation of functionally incompetent B lymphocytes, which are usually monoclonal in origin.

Hear from a panel of experts discussing how to navigate the landscape of food allergies.

Hear from a panel of experts discussing how to optimize the management of inherited blood disorders.

This non-promotional, sponsored webinar will review health plan best practice recommendations for Chronic Lymphocytic Leukemia (CLL) with an impressive panel of oncology and managed care experts.

Recommendations for treatment initiation in CLL are stratified by disease stage using either the Rai staging system, which defines disease as low-, intermediate-, or high-risk; or the Binet staging system, which defines disease as stage A, B, or C based on the number of lymphoid areas involved and the presence of anemia or thrombocytopenia. Generally, treatment should be initiated in patients with active or progressive disease who are intermediate- or high-risk, or stage B or C.